|
Active substance |
carfilzomib |
|
Holder |
Amgen N.V. |
|
Status |
Closed |
|
Indication |
in combination with lenalidomide and dexamethasone (KRd) for the treatment of adult patients with relapsed multiple myeloma who did receive at least 1 prior therapy |
|
Public documents |
|
|
Last update |
31/10/2016 |
Kyprolis®
Last updated on 03/04/2024